Roche says Avastin ovary cancer data "substantial" (Reuters)

Reuters - Swiss drugmaker Roche said it would report strong results with its top-selling cancer drug Avastin in ovarian cancer and reiterated the new use could add another 1 billion Swiss francs ($865 million) to sales.

This entry was posted on Friday, May 21st, 2010 at 10:51 am and is filed under Health. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.